On May 2, 2022, Abbott Laboratories announced that at its annual general meeting of shareholder held on April 29, 2022, the shareholders rejected a shareholder proposal requesting that the Company's Board of Directors adopt a policy that the Board Chairman be an independent director.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
106.9 USD | -0.03% | +1.51% | -2.92% |
Apr. 23 | Daiwa Securities Trims Abbott Laboratories Price Target to $125 From $126 | MT |
Apr. 22 | Barclays Adjusts Abbott Laboratories' Price Target to $140 From $141, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.92% | 185B | |
-3.80% | 107B | |
-5.48% | 67.55B | |
+11.22% | 54.6B | |
+16.74% | 47.42B | |
+3.86% | 42.24B | |
+4.56% | 28.24B | |
+1.64% | 26.42B | |
+12.40% | 25.66B | |
-1.60% | 24.9B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Declaration of Voting Results by Abbott Laboratories